Comment on 'The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-α inhibitor: a systematic review and meta-analysis': risk of cancer recurrence with biologics in psoriasis.

This article reviews the findings of Wu et al. regarding the risk of malignancy in patients with psoriasis who were treated with long-term tumour necrosis factor-α inhibitors. While the study found no significant increase in the risk of most cancers, it highlighted a higher risk of nonmelanoma skin cancers, particularly squamous cell carcinoma, in patients with psoriatic arthritis. The article discusses the clinical implications for patients with psoriasis who have a history of malignancy, advocating for a personalized treatment approach, vigilant monitoring and the need for further research to better understand the relationship between biologic therapy and cancer recurrence.